Are Biotechs the New Dot-Coms?

It is impossible to escape the Biotech bubble talk. There are fair points on both sides of the aisle, but rather than giving an opinion on how many people are currently participating or how stretched their valuations are, I want to look at how Biotechs have performed relative to the dot-com bubble.